S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
Log in

Aerie Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:AERI)

$17.85
-1.02 (-5.41 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$17.77
Now: $17.85
$18.92
50-Day Range
$17.79
MA: $20.39
$24.36
52-Week Range
$17.51
Now: $17.85
$50.10
Volume1.11 million shs
Average Volume891,203 shs
Market Capitalization$826.83 million
P/E RatioN/A
Dividend YieldN/A
Beta0.51
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AERI
CUSIPN/A
Phone919-237-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.18 million
Book Value$5.01 per share

Profitability

Net Income$-232,570,000.00
Net Margins-328.34%

Miscellaneous

Employees353
Market Cap$826.83 million
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive AERI News and Ratings via Email

Sign-up to receive the latest news and ratings for AERI and its competitors with MarketBeat's FREE daily newsletter.


Aerie Pharmaceuticals (NASDAQ:AERI) Frequently Asked Questions

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals Inc (NASDAQ:AERI) posted its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.86) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.84) by $0.02. The business earned $18.54 million during the quarter, compared to analyst estimates of $17.59 million. Aerie Pharmaceuticals had a negative return on equity of 77.63% and a negative net margin of 328.34%. View Aerie Pharmaceuticals' Earnings History.

When is Aerie Pharmaceuticals' next earnings date?

Aerie Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Aerie Pharmaceuticals.

What price target have analysts set for AERI?

11 brokerages have issued 1 year price objectives for Aerie Pharmaceuticals' shares. Their forecasts range from $25.00 to $56.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $43.18 in the next twelve months. This suggests a possible upside of 141.9% from the stock's current price. View Analyst Price Targets for Aerie Pharmaceuticals.

What is the consensus analysts' recommendation for Aerie Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aerie Pharmaceuticals.

What are Wall Street analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "We recently lowered our 2019 revenue to just under $80M vs. prior guidance of $110-120M, and Aeri just lowered to $70-80M. While this looks far below consensus of $98M, we believe current expectation were more in the $85M range, thus guidance is not too far below that. Importantly, we believe the guidance is very achievable, and based only on what the company is already seeing internally in terms of orders, leading indicators and managed care progress, rather than on aggressive market-research based assumptions." (8/8/2019)
  • 2. According to Zacks Investment Research, "The uptake of Aerie’s lead drug, Rhopressa, has been strong so far. The drug continues to gain traction with an increase in covered lives under various Medicare plans. The approval of the second drug, Rocklatan, a once-daily, quadruple-action fixed-dose combination of Rhopressa and Xalatan, has boosted the company’s portfolio and should propel sales in the coming quarters as glaucoma is one of the largest segments in the global ophthalmic market. We are also impressed with the company’s efforts to develop and boost pipeline. The company is evaluating possible uses of its proprietary portfolio of Rho Kinase inhibitors beyond glaucoma. Shares have outperformed the industry in the year so far. While the glaucoma market holds potential, Aerie faces stiff competition from existing players and new ones like Vyzulta, among others." (6/28/2019)
  • 3. Mizuho analysts commented, "We adjusted our 1Q19 revenue estimate for Rhopressa down but maintain our FY2019 net revenue estimate at the high-end of guidance. We expect Rhopressa Scripts to pick up around June driven by higher anticipated formulary coverage (Medicare Part D going from ~40% currently to ~70%+ in May – guided by management)." (4/21/2019)

Has Aerie Pharmaceuticals been receiving favorable news coverage?

News articles about AERI stock have been trending neutral recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aerie Pharmaceuticals earned a daily sentiment score of 0.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Aerie Pharmaceuticals.

Are investors shorting Aerie Pharmaceuticals?

Aerie Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 14,960,000 shares, an increase of 7.7% from the September 30th total of 13,890,000 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is presently 11.0 days. Currently, 37.6% of the company's shares are sold short. View Aerie Pharmaceuticals' Current Options Chain.

Who are some of Aerie Pharmaceuticals' key competitors?

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Canopy Growth (CGC), NicOx (NICXF), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Plug Power (PLUG), Micron Technology (MU), NVIDIA (NVDA), Incyte (INCY) and Alibaba Group (BABA).

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:
  • Dr. Vicente J. Anido Jr., CEO & Chairman (Age 66)
  • Mr. Thomas A. Mitro, Pres & COO (Age 61)
  • Dr. Casey C. Kopczynski, Co-Founder & Chief Scientific Officer (Age 58)
  • Mr. Richard James Rubino CPA, CFO, Sec. & Treasurer (Age 61)
  • Ms. Jessica Crespo CPA, Director of Accounting

Who are Aerie Pharmaceuticals' major shareholders?

Aerie Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.58%), C WorldWide Group Holding A S (1.21%), Rhenman & Partners Asset Management AB (1.03%), Provident Investment Management Inc. (0.81%), Handelsbanken Fonder AB (0.67%) and Kornitzer Capital Management Inc. KS (0.62%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino, Thomas A Mitro and Vicente Anido Jr. View Institutional Ownership Trends for Aerie Pharmaceuticals.

Which major investors are selling Aerie Pharmaceuticals stock?

AERI stock was sold by a variety of institutional investors in the last quarter, including Handelsbanken Fonder AB, Chartwell Investment Partners LLC, Provident Investment Management Inc., Oppenheimer & Co. Inc., Dupont Capital Management Corp, Granite Point Capital Management L.P. and Creative Planning. View Insider Buying and Selling for Aerie Pharmaceuticals.

Which major investors are buying Aerie Pharmaceuticals stock?

AERI stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Rice Hall James & Associates LLC, CNA Financial Corp, Kornitzer Capital Management Inc. KS, C WorldWide Group Holding A S, California Public Employees Retirement System, CWM LLC and Thompson Investment Management Inc.. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr. View Insider Buying and Selling for Aerie Pharmaceuticals.

How do I buy shares of Aerie Pharmaceuticals?

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $17.85.

How big of a company is Aerie Pharmaceuticals?

Aerie Pharmaceuticals has a market capitalization of $826.83 million and generates $24.18 million in revenue each year. The company earns $-232,570,000.00 in net income (profit) each year or ($4.65) on an earnings per share basis. Aerie Pharmaceuticals employs 353 workers across the globe.View Additional Information About Aerie Pharmaceuticals.

What is Aerie Pharmaceuticals' official website?

The official website for Aerie Pharmaceuticals is http://www.aeriepharma.com/.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]


MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  709 (Vote Outperform)
Underperform Votes:  433 (Vote Underperform)
Total Votes:  1,142
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe AERI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AERI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel